Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions

Figures & data

Table 1 The Cytokine Concentrations are as Follows

Time	Sample	IL-2 pg/mL	IL-4 pg/mL	IL-10 pg/mL	IL-6 pg/mL	IL-17A pg/mL	TNF-α pg/mL	IFN-γ pg/mL	Granzyme-A pg/mL	Granzyme-B pg/mL	Perforin pg/mL	Granulysin pg/mL
9 June 2020	Peripheral blood	<8.17	1.48	85.23	12.00	<1.28	<1.80	<3.43	20.88	9.13	986.97	655.00
9 June 2020	Right pleural effusion	<8.17	<1.18	1488.16	4884.91	<1.28	2.37	<3.43	57.52	721.32	1108.74	550.25
15 June 2020	Right pleural effusion	1301.42	7.56	1.62	2685.95	795.89	22.75	15.22	319.46	1141.92	3517.97	1668.17
17 August 2020	Left pleural effusion	15.05	0.83	1027.33	11,088.80	<1.28	5.54	9.32	100.27	435.53	243.55	945.15

Abbreviations: IL-2, interleukin 2; IL-4, interleukin 4; IL-10, interleukin 10; IL-6, interleukin 6; IL-17A, interleukin 17A; TNF-α, tumor necrosis factor α; IFN-γ, interferon γ.

Figure 1 Changes in chest CT findings during the course of the disease. (A) Taken on 8 June 2020, Initial stage: Chest CT showed bilateral pleural effusion as well as left interlobar effusion and no manifestation of acute inflammation and space-occupying lesions. (B) Taken on 15 July 2020, Remission stage: slowly increasing tendency of the left pleural effusion and no increasing in right pleural effusion. (C) Taken on 17 August 2020, Relapse stage: obvious increase of left pleural effusion and decrease of right pleural effusion. (D) Taken on 3 September 2020, Terminal stage: Ground-glass opacity and consolidation in the right lung, diffuse ground-glass opacity in the left lung, the progression of lesions in upper lobe and decrease of bilateral pleural effusion.